Is Celestica The Best AI Stock to Buy Now?
Technology and hardware business Celestica (NYSE:CLS) has seen massive upward…
Sell
36
CHRS Quote, Financials, Valuation and Earnings
Last price:
$1.64
Seasonality move
:
-3.09%
Day range:
$1.62 - $1.74
52-week range:
$0.71 - $2.62
Dividend yield:
0%
P/E ratio:
1.06x
P/S ratio:
2.26x
P/B ratio:
2.24x
Volume:
1.4M
Avg. volume:
3.2M
1-year change:
48.18%
Market cap:
$197M
Revenue:
$267M
EPS (TTM):
-$1.59
Price Performance History
Performance vs. Valuation Benchmarks
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Competitors
| Company | Revenue Forecast | Earnings Forecast | Revenue Growth Forecast | Earnings Growth Forecast | Analyst Price Target Median |
|---|---|---|---|---|---|
|
CHRS
Coherus Oncology, Inc.
|
$38.4M | -$0.31 | -73.97% | -29.42% | $6.75 |
|
ALLO
Allogene Therapeutics, Inc.
|
$3.3K | -$0.22 | -92.41% | -23.1% | $7.38 |
|
AVXL
Anavex Life Sciences Corp.
|
-- | -$0.08 | -- | -43.01% | $22.00 |
|
CRMD
CorMedix, Inc.
|
$94M | $0.52 | 178.58% | 96.01% | $14.86 |
|
VRTX
Vertex Pharmaceuticals, Inc.
|
$3.2B | $4.74 | 11.14% | 77% | $530.70 |
|
VSTM
Verastem, Inc.
|
$26.3M | -$0.44 | -88.84% | -44.38% | $17.00 |
| Company | Price | Analyst Target | Market Cap | P/E Ratio | Dividend per Share | Dividend Yield | Price / LTM Sales |
|---|---|---|---|---|---|---|---|
|
CHRS
Coherus Oncology, Inc.
|
$1.63 | $6.75 | $197M | 1.06x | $0.00 | 0% | 2.26x |
|
ALLO
Allogene Therapeutics, Inc.
|
$2.05 | $7.38 | $460.7M | -- | $0.00 | 0% | 2,442.58x |
|
AVXL
Anavex Life Sciences Corp.
|
$4.12 | $22.00 | $381.8M | -- | $0.00 | 0% | -- |
|
CRMD
CorMedix, Inc.
|
$7.03 | $14.86 | $553.9M | 3.42x | $0.00 | 0% | 2.37x |
|
VRTX
Vertex Pharmaceuticals, Inc.
|
$476.90 | $530.70 | $121.1B | 31.10x | $0.00 | 0% | 10.19x |
|
VSTM
Verastem, Inc.
|
$5.93 | $17.00 | $446.6M | -- | $0.00 | 0% | 27.71x |
| Company | Total Debt / Total Capital | Beta | Debt to Equity | Quick Ratio |
|---|---|---|---|---|
|
CHRS
Coherus Oncology, Inc.
|
38.23% | 1.563 | 28.5% | 0.54x |
|
ALLO
Allogene Therapeutics, Inc.
|
21.26% | -0.209 | 30.77% | 7.92x |
|
AVXL
Anavex Life Sciences Corp.
|
-- | -0.091 | -- | 20.68x |
|
CRMD
CorMedix, Inc.
|
1.16% | 2.679 | 0.48% | 1.60x |
|
VRTX
Vertex Pharmaceuticals, Inc.
|
9.84% | -0.890 | 1.77% | 2.24x |
|
VSTM
Verastem, Inc.
|
121% | -1.406 | 15.18% | 2.42x |
| Company | Gross Profit | Operating Income | Return on Invested Capital | Return on Common Equity | EBIT Margin | Free Cash Flow |
|---|---|---|---|---|---|---|
|
CHRS
Coherus Oncology, Inc.
|
$6.9M | -$42.2M | -115.69% | -- | -364.99% | -$46.3M |
|
ALLO
Allogene Therapeutics, Inc.
|
-$3.1M | -$44.9M | -44.62% | -54.89% | -315927.27% | -$29.9M |
|
AVXL
Anavex Life Sciences Corp.
|
-- | -$6.8M | -38.18% | -38.18% | -- | -$7.2M |
|
CRMD
CorMedix, Inc.
|
$93.1M | $51.3M | 94.54% | 95.25% | 49.24% | $30.4M |
|
VRTX
Vertex Pharmaceuticals, Inc.
|
$2.8B | $1.3B | 20.84% | 22.97% | 40.3% | $348.6M |
|
VSTM
Verastem, Inc.
|
$9.3M | -$40.7M | -369.69% | -1773.4% | -362.17% | -$44.5M |
Coherus Oncology, Inc. vs. Competitors
-
Which has Higher Returns CHRS or ALLO?
Allogene Therapeutics, Inc. has a net margin of -384.73% compared to Coherus Oncology, Inc.'s net margin of -295454.55%. Coherus Oncology, Inc.'s return on equity of -- beat Allogene Therapeutics, Inc.'s return on equity of -54.89%.
Company Gross Margin Earnings Per Share Invested Capital CHRSCoherus Oncology, Inc.59.49% -$0.30 $142.1M ALLOAllogene Therapeutics, Inc.-- -$0.19 $400.5M -
What do Analysts Say About CHRS or ALLO?
Coherus Oncology, Inc. has a consensus price target of $6.75, signalling upside risk potential of 314.11%. On the other hand Allogene Therapeutics, Inc. has an analysts' consensus of $7.38 which suggests that it could grow by 260.16%. Given that Coherus Oncology, Inc. has higher upside potential than Allogene Therapeutics, Inc., analysts believe Coherus Oncology, Inc. is more attractive than Allogene Therapeutics, Inc..
Company Buy Ratings Hold Ratings Sell Ratings CHRSCoherus Oncology, Inc.4 1 0 ALLOAllogene Therapeutics, Inc.10 1 0 -
Is CHRS or ALLO More Risky?
Coherus Oncology, Inc. has a beta of 0.991, which suggesting that the stock is 0.884% less volatile than S&P 500. In comparison Allogene Therapeutics, Inc. has a beta of 0.603, suggesting its less volatile than the S&P 500 by 39.696%.
-
Which is a Better Dividend Stock CHRS or ALLO?
Coherus Oncology, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Allogene Therapeutics, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Coherus Oncology, Inc. pays -- of its earnings as a dividend. Allogene Therapeutics, Inc. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios CHRS or ALLO?
Coherus Oncology, Inc. quarterly revenues are $11.6M, which are larger than Allogene Therapeutics, Inc. quarterly revenues of --. Coherus Oncology, Inc.'s net income of -$44.5M is lower than Allogene Therapeutics, Inc.'s net income of -$41.4M. Notably, Coherus Oncology, Inc.'s price-to-earnings ratio is 1.06x while Allogene Therapeutics, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Coherus Oncology, Inc. is 2.26x versus 2,442.58x for Allogene Therapeutics, Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income CHRSCoherus Oncology, Inc.2.26x 1.06x $11.6M -$44.5M ALLOAllogene Therapeutics, Inc.2,442.58x -- -- -$41.4M
-
Which has Higher Returns CHRS or AVXL?
Anavex Life Sciences Corp. has a net margin of -384.73% compared to Coherus Oncology, Inc.'s net margin of --. Coherus Oncology, Inc.'s return on equity of -- beat Anavex Life Sciences Corp.'s return on equity of -38.18%.
Company Gross Margin Earnings Per Share Invested Capital CHRSCoherus Oncology, Inc.59.49% -$0.30 $142.1M AVXLAnavex Life Sciences Corp.-- -$0.06 $126.6M -
What do Analysts Say About CHRS or AVXL?
Coherus Oncology, Inc. has a consensus price target of $6.75, signalling upside risk potential of 314.11%. On the other hand Anavex Life Sciences Corp. has an analysts' consensus of $22.00 which suggests that it could grow by 433.98%. Given that Anavex Life Sciences Corp. has higher upside potential than Coherus Oncology, Inc., analysts believe Anavex Life Sciences Corp. is more attractive than Coherus Oncology, Inc..
Company Buy Ratings Hold Ratings Sell Ratings CHRSCoherus Oncology, Inc.4 1 0 AVXLAnavex Life Sciences Corp.2 1 0 -
Is CHRS or AVXL More Risky?
Coherus Oncology, Inc. has a beta of 0.991, which suggesting that the stock is 0.884% less volatile than S&P 500. In comparison Anavex Life Sciences Corp. has a beta of 1.212, suggesting its more volatile than the S&P 500 by 21.178%.
-
Which is a Better Dividend Stock CHRS or AVXL?
Coherus Oncology, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Anavex Life Sciences Corp. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Coherus Oncology, Inc. pays -- of its earnings as a dividend. Anavex Life Sciences Corp. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios CHRS or AVXL?
Coherus Oncology, Inc. quarterly revenues are $11.6M, which are larger than Anavex Life Sciences Corp. quarterly revenues of --. Coherus Oncology, Inc.'s net income of -$44.5M is lower than Anavex Life Sciences Corp.'s net income of -$5.7M. Notably, Coherus Oncology, Inc.'s price-to-earnings ratio is 1.06x while Anavex Life Sciences Corp.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Coherus Oncology, Inc. is 2.26x versus -- for Anavex Life Sciences Corp.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income CHRSCoherus Oncology, Inc.2.26x 1.06x $11.6M -$44.5M AVXLAnavex Life Sciences Corp.-- -- -- -$5.7M
-
Which has Higher Returns CHRS or CRMD?
CorMedix, Inc. has a net margin of -384.73% compared to Coherus Oncology, Inc.'s net margin of 49.9%. Coherus Oncology, Inc.'s return on equity of -- beat CorMedix, Inc.'s return on equity of 95.25%.
Company Gross Margin Earnings Per Share Invested Capital CHRSCoherus Oncology, Inc.59.49% -$0.30 $142.1M CRMDCorMedix, Inc.89.26% $1.26 $378.5M -
What do Analysts Say About CHRS or CRMD?
Coherus Oncology, Inc. has a consensus price target of $6.75, signalling upside risk potential of 314.11%. On the other hand CorMedix, Inc. has an analysts' consensus of $14.86 which suggests that it could grow by 111.34%. Given that Coherus Oncology, Inc. has higher upside potential than CorMedix, Inc., analysts believe Coherus Oncology, Inc. is more attractive than CorMedix, Inc..
Company Buy Ratings Hold Ratings Sell Ratings CHRSCoherus Oncology, Inc.4 1 0 CRMDCorMedix, Inc.4 0 0 -
Is CHRS or CRMD More Risky?
Coherus Oncology, Inc. has a beta of 0.991, which suggesting that the stock is 0.884% less volatile than S&P 500. In comparison CorMedix, Inc. has a beta of 1.388, suggesting its more volatile than the S&P 500 by 38.76%.
-
Which is a Better Dividend Stock CHRS or CRMD?
Coherus Oncology, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. CorMedix, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Coherus Oncology, Inc. pays -- of its earnings as a dividend. CorMedix, Inc. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios CHRS or CRMD?
Coherus Oncology, Inc. quarterly revenues are $11.6M, which are smaller than CorMedix, Inc. quarterly revenues of $104.3M. Coherus Oncology, Inc.'s net income of -$44.5M is lower than CorMedix, Inc.'s net income of $108.6M. Notably, Coherus Oncology, Inc.'s price-to-earnings ratio is 1.06x while CorMedix, Inc.'s PE ratio is 3.42x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Coherus Oncology, Inc. is 2.26x versus 2.37x for CorMedix, Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income CHRSCoherus Oncology, Inc.2.26x 1.06x $11.6M -$44.5M CRMDCorMedix, Inc.2.37x 3.42x $104.3M $108.6M
-
Which has Higher Returns CHRS or VRTX?
Vertex Pharmaceuticals, Inc. has a net margin of -384.73% compared to Coherus Oncology, Inc.'s net margin of 36.91%. Coherus Oncology, Inc.'s return on equity of -- beat Vertex Pharmaceuticals, Inc.'s return on equity of 22.97%.
Company Gross Margin Earnings Per Share Invested Capital CHRSCoherus Oncology, Inc.59.49% -$0.30 $142.1M VRTXVertex Pharmaceuticals, Inc.85.56% $4.65 $20.7B -
What do Analysts Say About CHRS or VRTX?
Coherus Oncology, Inc. has a consensus price target of $6.75, signalling upside risk potential of 314.11%. On the other hand Vertex Pharmaceuticals, Inc. has an analysts' consensus of $530.70 which suggests that it could grow by 11.28%. Given that Coherus Oncology, Inc. has higher upside potential than Vertex Pharmaceuticals, Inc., analysts believe Coherus Oncology, Inc. is more attractive than Vertex Pharmaceuticals, Inc..
Company Buy Ratings Hold Ratings Sell Ratings CHRSCoherus Oncology, Inc.4 1 0 VRTXVertex Pharmaceuticals, Inc.21 5 1 -
Is CHRS or VRTX More Risky?
Coherus Oncology, Inc. has a beta of 0.991, which suggesting that the stock is 0.884% less volatile than S&P 500. In comparison Vertex Pharmaceuticals, Inc. has a beta of 0.303, suggesting its less volatile than the S&P 500 by 69.725%.
-
Which is a Better Dividend Stock CHRS or VRTX?
Coherus Oncology, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Vertex Pharmaceuticals, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Coherus Oncology, Inc. pays -- of its earnings as a dividend. Vertex Pharmaceuticals, Inc. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios CHRS or VRTX?
Coherus Oncology, Inc. quarterly revenues are $11.6M, which are smaller than Vertex Pharmaceuticals, Inc. quarterly revenues of $3.2B. Coherus Oncology, Inc.'s net income of -$44.5M is lower than Vertex Pharmaceuticals, Inc.'s net income of $1.2B. Notably, Coherus Oncology, Inc.'s price-to-earnings ratio is 1.06x while Vertex Pharmaceuticals, Inc.'s PE ratio is 31.10x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Coherus Oncology, Inc. is 2.26x versus 10.19x for Vertex Pharmaceuticals, Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income CHRSCoherus Oncology, Inc.2.26x 1.06x $11.6M -$44.5M VRTXVertex Pharmaceuticals, Inc.10.19x 31.10x $3.2B $1.2B
-
Which has Higher Returns CHRS or VSTM?
Verastem, Inc. has a net margin of -384.73% compared to Coherus Oncology, Inc.'s net margin of -876.34%. Coherus Oncology, Inc.'s return on equity of -- beat Verastem, Inc.'s return on equity of -1773.4%.
Company Gross Margin Earnings Per Share Invested Capital CHRSCoherus Oncology, Inc.59.49% -$0.30 $142.1M VSTMVerastem, Inc.82.57% -$1.35 $74M -
What do Analysts Say About CHRS or VSTM?
Coherus Oncology, Inc. has a consensus price target of $6.75, signalling upside risk potential of 314.11%. On the other hand Verastem, Inc. has an analysts' consensus of $17.00 which suggests that it could grow by 180.35%. Given that Coherus Oncology, Inc. has higher upside potential than Verastem, Inc., analysts believe Coherus Oncology, Inc. is more attractive than Verastem, Inc..
Company Buy Ratings Hold Ratings Sell Ratings CHRSCoherus Oncology, Inc.4 1 0 VSTMVerastem, Inc.8 0 0 -
Is CHRS or VSTM More Risky?
Coherus Oncology, Inc. has a beta of 0.991, which suggesting that the stock is 0.884% less volatile than S&P 500. In comparison Verastem, Inc. has a beta of 0.414, suggesting its less volatile than the S&P 500 by 58.56%.
-
Which is a Better Dividend Stock CHRS or VSTM?
Coherus Oncology, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Verastem, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Coherus Oncology, Inc. pays -- of its earnings as a dividend. Verastem, Inc. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios CHRS or VSTM?
Coherus Oncology, Inc. quarterly revenues are $11.6M, which are larger than Verastem, Inc. quarterly revenues of $11.2M. Coherus Oncology, Inc.'s net income of -$44.5M is higher than Verastem, Inc.'s net income of -$98.5M. Notably, Coherus Oncology, Inc.'s price-to-earnings ratio is 1.06x while Verastem, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Coherus Oncology, Inc. is 2.26x versus 27.71x for Verastem, Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income CHRSCoherus Oncology, Inc.2.26x 1.06x $11.6M -$44.5M VSTMVerastem, Inc.27.71x -- $11.2M -$98.5M
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
Will AI Disrupt SaaS Software Stocks?
Since January 28th, software stocks in the United States have…
Why Is Meta Stock Going Higher?
Over the last five days, shares of Instagram and Facebook…
Stock Ideas
Buy
55
Is NVDA Stock a Buy?
Market Cap: $4.6T
P/E Ratio: 65x
Sell
50
Is AAPL Stock a Buy?
Market Cap: $3.9T
P/E Ratio: 35x
Sell
40
Is GOOGL Stock a Buy?
Market Cap: $3.8T
P/E Ratio: 29x
Alerts
Buy
77
RNG alert for Feb 21
RingCentral, Inc. [RNG] is up 34.37% over the past day.
Sell
9
FROG alert for Feb 21
JFrog Ltd. [FROG] is down 24.98% over the past day.
Buy
72
SNSE alert for Feb 21
Sensei Biotherapeutics, Inc. [SNSE] is up 23.81% over the past day.
